{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:30:31Z","timestamp":1790224231533,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vernakalant is approved in Europe, Canada, and several Asian countries for the pharmacological cardioversion of recent-onset atrial fibrillation (AF), but remains unauthorized in the United States due to FDA safety concerns. Its role in emergency department (ED) management of AF requires further comparative evaluation against other agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study including all AF episodes treated with intravenous (iv) vernakalant, flecainide, or amiodarone in a single ED between January 2012 and December 2022. Clinical data were extracted from patient records. The primary outcome was sinus rhythm (SR) conversion during the ED stay. Secondary outcomes included time to SR, ED length of stay, AF recurrence, ED revisits, and rehospitalizations within 6 months, as well as adverse events (AEs) occurring during drug infusion or during the ED stay. Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline confounding. Subgroup analyses explored the impact of demographic and clinical variables on treatment response and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We analyzed 899 AF episodes (vernakalant: 262; flecainide: 151; amiodarone: 486). SR conversion rates were 76.7% (vernakalant), 69.5% (flecainide), and 67.3% (amiodarone). Median time to SR was significantly shorter with vernakalant (0.25\u00a0h), compared to flecainide (2.58\u00a0h) and amiodarone (8\u00a0h;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Vernakalant was associated with shorter ED stays. During follow-up, ED revisits and rehospitalizations occurred less frequently in vernakalant-treated patients than in amiodarone-treated patients, although these findings should be interpreted cautiously given baseline differences between groups. AEs occurred in 15.3% (vernakalant), 16.6% (flecainide), and 12.6% (amiodarone); flecainide showed a higher incidence of AEs of special interest. In patients with NYHA class I\u2013II heart failure, vernakalant showed increased efficacy but also higher AE rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vernakalant showed comparable overall efficacy to amiodarone and flecainide for cardioversion of recent-onset AF, with faster SR conversion and shorter ED stays. However, given the retrospective design, non-random treatment allocation, and baseline differences between groups, these comparative findings should be interpreted with caution. Vernakalant may be a useful option in selected patients when rapid cardioversion is desired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12873-026-01604-w","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:25:19Z","timestamp":1778124319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effectiveness and safety of vernakalant, flecainide, and amiodarone for atrial fibrillation cardioversion: a propensity score\u2013matched analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Giuseppe","family":"Dominijanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio F.","family":"Caballero-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Pineda-Torcuato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sainz-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Capilla-Pueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Ruiz-Antor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"1604_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193.","journal-title":"Circulation"},{"issue":"4","key":"1604_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jama.2024.22451","volume":"333","author":"D Ko","year":"2025","unstructured":"Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH. Atrial Fibrillation. JAMA. 2025;333(4):329. https:\/\/doi.org\/10.1001\/jama.2024.22451.","journal-title":"JAMA"},{"issue":"4","key":"1604_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJMcp2023658","volume":"384","author":"GF Michaud","year":"2021","unstructured":"Michaud GF, Stevenson WG. Atrial Fibrillation. Solomon CG. ed N Engl J Med. 2021;384(4):353\u201361. https:\/\/doi.org\/10.1056\/NEJMcp2023658.","journal-title":"ed N Engl J Med"},{"key":"1604_CR4","doi-asserted-by":"publisher","unstructured":"Chyou JY, Barkoudah E, Dukes JW, et al. Atrial fibrillation occurring during acute hospitalization: a scientific statement from the American heart association. Circulation. 2023;147(15). https:\/\/doi.org\/10.1161\/CIR.0000000000001133.","DOI":"10.1161\/CIR.0000000000001133"},{"issue":"5","key":"1604_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"key":"1604_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ajem.2021.07.055","volume":"50","author":"M Varona","year":"2021","unstructured":"Varona M, Coll-Vinent B, Mart\u00edn A, et al. Factors associated with poor prognosis in patients with atrial fibrillation: An emergency department perspective the EMERG-AF study. Am J Emerg Med. 2021;50:270\u20137. https:\/\/doi.org\/10.1016\/j.ajem.2021.07.055.","journal-title":"Am J Emerg Med"},{"key":"1604_CR7","unstructured":"Carbajosa Dalmau J, Cos\u00edn-Sales J, P\u00e9rez-Dur\u00e1 MJ, et al. Vernakalant in hospital emergency practice: safety and effectiveness. Emergencias. 2017; 29(6):397\u2013402. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29188914"},{"issue":"1","key":"1604_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.annemergmed.2020.01.013","volume":"76","author":"IS deSouza","year":"2020","unstructured":"deSouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. Ann Emerg Med. 2020;76(1):14\u201330. https:\/\/doi.org\/10.1016\/j.annemergmed.2020.01.013.","journal-title":"Ann Emerg Med"},{"issue":"6","key":"1604_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00228-022-03296-0","volume":"78","author":"D Tsiachris","year":"2022","unstructured":"Tsiachris D, Doundoulakis I, Tsioufis P, et al. Reappraising the role of class Ic antiarrhythmics in atrial fibrillation. Eur J Clin Pharmacol. 2022;78(6):1039\u201345. https:\/\/doi.org\/10.1007\/s00228-022-03296-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1604_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12245-025-00951-y","volume":"18","author":"G Dominijanni","year":"2025","unstructured":"Dominijanni G, Caballero-Bermejo AF, Sainz-Herrero A, Pineda-Torcuato \u00c1, Capilla-Pueyo R, Ruiz-Antor\u00e1n B. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study. Int J Emerg Med. 2025;18(1):141. https:\/\/doi.org\/10.1186\/s12245-025-00951-y.","journal-title":"Int J Emerg Med"},{"issue":"1","key":"1604_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12873-025-01280-2","volume":"25","author":"G Dominijanni","year":"2025","unstructured":"Dominijanni G, Caballero-Bermejo AF, Pineda-Torcuato \u00c1, Sainz-Herrero A, Capilla-Pueyo R, Ruiz-Antor\u00e1n B. Real-world experience with vernakalant in the urgent management of atrial fibrillation: results from the VERITA study. BMC Emerg Med. 2025;25(1):118. https:\/\/doi.org\/10.1186\/s12873-025-01280-2.","journal-title":"BMC Emerg Med"},{"issue":"10","key":"1604_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cardfail.2014.07.013","volume":"20","author":"G Frommeyer","year":"2014","unstructured":"Frommeyer G, Schulze Grotthoff J, Fischer C, et al. Vernakalant in an Experimental Model of Pacing-Induced Heart Failure: Lack of Proarrhythmia Despite Prolongation of Repolarization. J Card Fail. 2014;20(10):786\u201392. https:\/\/doi.org\/10.1016\/j.cardfail.2014.07.013.","journal-title":"J Card Fail"},{"key":"1604_CR13","doi-asserted-by":"publisher","first-page":"104521","DOI":"10.1016\/j.phrs.2019.104521","volume":"151","author":"N Mujovi\u0107","year":"2020","unstructured":"Mujovi\u0107 N, Dobrev D, Marinkovi\u0107 M, Russo V, Potpara TS. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020;151:104521. https:\/\/doi.org\/10.1016\/j.phrs.2019.104521.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1604_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/2048872617728558","volume":"8","author":"H Pohjant\u00e4hti-Maaroos","year":"2019","unstructured":"Pohjant\u00e4hti-Maaroos H, Hypp\u00f6l\u00e4 H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Hear J Acute Cardiovasc care. 2019;8(2):114\u201320. https:\/\/doi.org\/10.1177\/2048872617728558.","journal-title":"Eur Hear J Acute Cardiovasc care"},{"issue":"10","key":"1604_CR15","doi-asserted-by":"publisher","first-page":"1330e13","DOI":"10.1016\/j.cjca.2013.01.002","volume":"29","author":"D Conde","year":"2013","unstructured":"Conde D, Costabel JP, Aragon M, et al. Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation. Can J Cardiol. 2013;29(10):1330e13. https:\/\/doi.org\/10.1016\/j.cjca.2013.01.002.","journal-title":"Can J Cardiol"},{"issue":"4","key":"1604_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/europace\/eun048","volume":"10","author":"A Ringborg","year":"2008","unstructured":"Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10(4):403\u201311. https:\/\/doi.org\/10.1093\/europace\/eun048.","journal-title":"Europace"},{"issue":"2","key":"1604_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10557-020-07127-1","volume":"35","author":"D Tsiachris","year":"2021","unstructured":"Tsiachris D, Doundoulakis I, Pagkalidou E, et al. Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis. Cardiovasc drugs Ther. 2021;35(2):293\u2013308. https:\/\/doi.org\/10.1007\/s10557-020-07127-1.","journal-title":"Cardiovasc drugs Ther"},{"issue":"2","key":"1604_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10557-012-6374-4","volume":"26","author":"LD Bash","year":"2012","unstructured":"Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc drugs Ther. 2012;26(2):167\u201379. https:\/\/doi.org\/10.1007\/s10557-012-6374-4.","journal-title":"Cardiovasc drugs Ther"},{"key":"1604_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07552-6","author":"IS deSouza","year":"2024","unstructured":"deSouza IS, Shrestha P, Allen R, Koos J, Thode H. Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis. Cardiovasc drugs Ther Febr. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07552-6.","journal-title":"Cardiovasc drugs Ther Febr"},{"issue":"3","key":"1604_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.55633\/s3me\/037.2024","volume":"36","author":"G Dominijanni","year":"2024","unstructured":"Dominijanni G, Caballero-Bermejo AF, Mart\u00edn Jim\u00e9nez ML, Calpe Delgado P, Rodr\u00edguez-Miranda B, Ruiz-Antor\u00e1n B. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study. Emergencias. 2024;36(3):239\u201340. https:\/\/doi.org\/10.55633\/s3me\/037.2024","journal-title":"Emergencias Rev la Soc Esp Med Emergencias"},{"issue":"3","key":"1604_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","volume":"57","author":"AJ Camm","year":"2011","unstructured":"Camm AJ, Capucci A, Hohnloser SH, et al. A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation. J Am Coll Cardiol. 2011;57(3):313\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2010.07.046.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1604_CR22","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1001\/archinte.167.15.1648","volume":"167","author":"V Essebag","year":"2007","unstructured":"Essebag V. Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. Arch Intern Med. 2007;167(15):1648. https:\/\/doi.org\/10.1001\/archinte.167.15.1648.","journal-title":"Arch Intern Med"},{"key":"1604_CR23","doi-asserted-by":"publisher","unstructured":"Coll-Vinent Puig B. Atrial fibrillation in women. Rev Espa\u00f1ola Urgencias y Emergencias. 2024 Sep. https:\/\/doi.org\/10.55633\/s3me\/REUE033.2024.","DOI":"10.55633\/s3me\/REUE033.2024"}],"container-title":["BMC Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12873-026-01604-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12873-026-01604-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12873-026-01604-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:29:20Z","timestamp":1782862160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12873-026-01604-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1604"],"URL":"https:\/\/doi.org\/10.1186\/s12873-026-01604-w","relation":{},"ISSN":["1471-227X"],"issn-type":[{"value":"1471-227X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hospital Universitario Puerta de Hierro\u2019s Research Ethics Committee (REC) (PI 73\/22) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was granted a waiver of informed consent by the REC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}